Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR Formative Research

Date Submitted: Jan 22, 2025
Date Accepted: Dec 10, 2025

The final, peer-reviewed published version of this preprint can be found here:

Misinformation and Profitability of Hepatitis B Virus Claims on Instagram: Formative Cross-Sectional Study

Warner ZG, Turner CA, Alvarez R, Gallegos-Orozco JF, Green A, Warner EL

Misinformation and Profitability of Hepatitis B Virus Claims on Instagram: Formative Cross-Sectional Study

JMIR Form Res 2026;10:e71584

DOI: 10.2196/71584

PMID: 41769926

PMCID: 12993275

Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.

Misinformation and profitability of Hepatitis B Virus claims on Instagram

  • Zachary G Warner; 
  • Cindy A Turner; 
  • Rodrigo Alvarez; 
  • Juan F Gallegos-Orozco; 
  • Ashley Green; 
  • Echo L Warner

ABSTRACT

Background:

Patients increasingly use the internet to find health information and social support, yet online health information is vastly unregulated and often contains misinformation. The chronic nature and high worldwide prevalence of Hepatitis B Virus (HBV) suggests it may be a common topic of online discourse, but the prevalence and reach of HBV online misinformation is understudied.

Objective:

To document the characteristics and prevalence of HBV misinformation in Instagram posts, factors that may influence the impact these posts have on viewers, and engagement with HVB misinformation on Instagram.

Methods:

In December 2021, we searched for publicly available Instagram posts using the terms “hepatitis b” and “hep b” and extracted data from the top posts and user profiles for each term. Each of the N=103 posts were coded for 58 variables including post characteristics, types of HBV claims (e.g., treatment, prevention, cure), presence of misinformation (determined by medical experts), engagement (e.g., number of likes), and profitability. We calculated descriptive and inferential statistics to describe the characteristics, prevalence, and reach of HBV claims by misinformation and profitability.

Results:

Over a quarter of posts (n=27, 26.2%) contained HBV misinformation. There was significantly more misinformation about treatment (55.6% vs. 44.4%), cures (75.0% vs. 25.0%), natural remedies (92.3% vs. 7.7%), symptoms (60.0% vs. 40.0%), and censorship (66.7% vs. 33.3%) than accurate information about these topics (all P<.01). Compared to accurate information, misinformation posts had more engagement (1,599.1 likes vs. 970.0 likes on average, P<.001). Significantly more misinformation posts were for profit (47% vs. 14%, P<.01) than accurate posts.

Conclusions:

HBV misinformation has more engagement than accurate information and is significantly more likely to be for profit. More research is needed to understand how exposure to health information can influence patient/caregiver behaviors, health disparities, and health outcomes.


 Citation

Please cite as:

Warner ZG, Turner CA, Alvarez R, Gallegos-Orozco JF, Green A, Warner EL

Misinformation and Profitability of Hepatitis B Virus Claims on Instagram: Formative Cross-Sectional Study

JMIR Form Res 2026;10:e71584

DOI: 10.2196/71584

PMID: 41769926

PMCID: 12993275

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.